Cantor Fitzgerald analyst Eliana Merle maintained a Buy rating on AnaptysBio Inc (ANAB) today and set a price target of $140. The company’s shares opened today at $71.48.
Merle wrote:
“(3/8) REV 1Q 2Q 3Q 4Q 2017A 0.0A 7.0A 0.0A 3.0A 2018E 0.0A 0.0A 5.0A 0.0E 2019E 0.0E 0.0E 10.0E 10.0E EPS 1Q 2Q 3Q 4Q 2017A (0.69)A (0.06)A (0.40)A (0.25)A 2018E (0.54)A (0.46)A (0.56)A (0.84)E 2019E (0.96)E (1.08)E (0.85)E (1.03)E FY 2017A 2018E 2019E REV 10.0A 5.0E 20.0E EPS (1.30)A (2.42)E (3.92)E.”
According to TipRanks.com, Merle is a 1-star analyst with an average return of -3.2% and a 25.0% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, CymaBay Therapeutics, and Galapagos NV.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $131.50 average price target, representing an 84.0% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $135 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $133.89 and a one-year low of $54.26. Currently, AnaptysBio Inc has an average volume of 276.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
